Mersana Therapeutics Receives “Reduce” Rating from Analysts

Mersana Therapeutics, Inc. (NASDAQ: MRSN) has been assigned an average consensus rating of “Reduce” by eight brokerages currently analyzing the stock. According to MarketBeat.com, one analyst has issued a sell rating while seven others recommend holding the stock. The average price target over the next 12 months stands at approximately $38.19.

Several firms recently adjusted their ratings for Mersana Therapeutics. On November 13, 2023, Lifesci Capital downgraded the company from a “strong-buy” to a “hold” rating. BTIG Research followed suit, changing its rating from a “buy” to a “hold.” Similarly, both Leerink Partners and Wedbush made comparable adjustments to their ratings on the same day. Truist Financial cut its rating from “buy” to “hold” while also reducing the price target from $36.00 to $30.75.

Financial Performance and Analyst Predictions

Mersana Therapeutics reported its quarterly earnings on November 14, 2023. The company posted a loss of ($1.51) earnings per share, falling short of analysts’ estimates of ($1.44) by $0.07. Revenue for the quarter totaled $11.01 million, which also did not meet the consensus estimate of $14.20 million. Analysts project that Mersana Therapeutics will report an earnings per share of (0.62) for the current year.

Investor Activity and Institutional Holdings

Recent transactions indicate a shift in institutional investor interest in Mersana Therapeutics. AQR Capital Management LLC acquired a new stake in the company valued at approximately $1.77 million during the first quarter. Acadian Asset Management LLC also purchased a new position worth about $1.03 million within the same timeframe.

683 Capital Management LLC increased its holdings by 20.6% in the second quarter, now owning 1,990,000 shares valued at $589,000 after acquiring an additional 340,000 shares. Jacobs Levy Equity Management Inc. raised its stake by 19.9%, now holding 1,333,124 shares worth $459,000. Notably, institutional investors currently own approximately 93.92% of Mersana Therapeutics’ stock.

About Mersana Therapeutics

Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody drug conjugates (ADC) for cancer patients with unmet medical needs. The company is working on several promising candidates, including XMT-1660, which targets B7-H4, and XMT-2056, an immunosynthen ADC. Collaborations with notable organizations such as Janssen Biotech, Inc., Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC bolster its research and development efforts.

As Mersana Therapeutics navigates these challenges and opportunities, investor confidence and market performance will be closely monitored in the coming months.